Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma

NCT02293005 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer
Mesothelioma

Interventions

DRUG: Alisertib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]